Citing an FDA warning letter and the company's revised FY13 guidance among other factors,...
Citing an FDA warning letter and the company's revised FY13 guidance among other factors, Moody's puts Hospira's (HSP -0.8%) long-term debt rating on review for downgrade. The ratings agency says "cash payouts associated with [HSP's new medical device] strategy, remediation costs, and the potential for lost sales once its branded injectible sedative, Precedex, loses patent protection" could hurt liquidity and tighten credit metrics.
From other sites
at Zacks.com (Apr 8, 2015)
at MarketWatch.com (Feb 12, 2015)
at Benzinga.com (Feb 12, 2015)
at MarketWatch.com (Feb 10, 2015)
at Investor's Business Daily (Feb 5, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs